Anatara Lifesciences Ltd (ASX:ANR)
Australia · Delayed Price · Currency is AUD 0.0120
-0.0020 (-14.29%)
Jan 30, 2026, 3:06 PM AEST
Anatara Lifesciences Company Description
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia.
The company’s products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and Detach for the treatment of diarrhea in piglets.
It also develops anti-obesity project, an oral medication to assist weight reduction and control. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.
Anatara Lifesciences Ltd
| Country | Australia |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | David Brookes |
Contact Details
Address: 81 Flinders Street Adelaide, SA 5000 Australia | |
| Phone | 61 4 3802 7172 |
| Website | anataralifesciences.com |
Stock Details
| Ticker Symbol | ANR |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000ANR0 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Lionel Brookes F.A.C.I.D., FACRRM, FAICD, MBBS | Executive Chairman and MD |
| Simon Erskine | Chief Development Officer |
| Jonathan Lindh | Company Secretary |
| Hayley van der Meer B Biomed Sc, Grad Dip Marketing Management | Commercial Manager |